FDA Approves GSK’s Arexvy to Prevent Respiratory Syncytial Virus in Adults Aged 50-59 with Increased Risk

Posted on June 11, 2024 by admin

Arexvy receives expanded indication to include adults aged 59 years and younger to prevent RSV lower respiratory tract disease.